Drugs / LAD191
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06488209 | Jul 2022 → Apr 2025 | autoimmune disease | Almirall, S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07151937 | Nov 2025 → May 2027 expected | hidradenitis suppurativa | Almirall, S.A. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-17 | Almirall, S.A. | Results EADV 2025: Almirall advances skin science and leads innovation for holistic patient care in medical dermatology almirall.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-17 | Almirall, S.A. | EADV 2025: Almirall advances skin science and leads innovation for holistic patient care in medical dermatology almirall.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAD191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07151937 ↗ |
| Route | Subcutaneous | “LAD191 SC injection.” NCT06488209 ↗ |